Keytruda is a brand name for pembrolizumab, which is a type of immunotherapy drug that is used to treat various types of cancer. It is manufactured by Merck & Co. and was first approved by the U.S. Food and Drug Administration (FDA) in 2014. Keytruda works by blocking a protein called PD-1 on immune cells, which allows the immune system to recognize and attack cancer cells more effectively [3].

Keytruda is approved to treat several types of cancer, including melanoma, non-small cell lung cancer, head and neck squamous cell carcinoma, classical Hodgkin lymphoma, urothelial carcinoma, microsatellite instability-high cancer, and gastric or gastroesophageal junction adenocarcinoma [1]. It is often used in combination with other cancer treatments, such as chemotherapy or radiation therapy.

Keytruda is administered intravenously, typically every three weeks, and the treatment duration depends on the type and stage of cancer being treated [2]. Like all medications, Keytruda may cause side effects, including fatigue, nausea, loss of appetite, and skin rash. However, many patients tolerate the drug well, and it has shown promising results in clinical trials.

In conclusion, Keytruda is a type of immunotherapy drug that is used to treat various types of cancer by blocking a protein called PD-1 on immune cells. It is approved to treat melanoma, non-small cell lung cancer, head and neck squamous cell carcinoma, classical Hodgkin lymphoma, urothelial carcinoma, microsatellite instability-high cancer, and gastric or gastroesophageal junction adenocarcinoma. Keytruda is often used in combination with other cancer treatments and is administered intravenously every three weeks. [1][2][3]

Sources:
[1] https://www.drugpatentwatch.com/p/biologics/tradename/KEYTRUDA
[2] https://www.keytruda.com/
[3] https://www.cancer.gov/publications/dictionaries/cancer-terms/def/keytruda